Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials
Climacteric. 2018 Apr;21(2):189-195Six randomized controlled trials were included in this meta-analysis which compared the effects of romosozumab to placebo, teriparatide, and alendronate in postmenopausal osteoporosis treatment. The change in bone mineral density at the lumbar spine, total hip, and femoral neck significantly favoured romosozumab versus both placebo and active controls. Fracture rates after 24 months also significantly favoured romosozumab, though comparison was made to a combined control group from 2 studies, and included patients administered placebo and alendronate.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
